Drug intelligence / Profile preview

ACM-007

Development stage: Preclinical
Lead developer: ACM Biolabs
Modality: Nanoparticles → Drug Delivery Systems
Administration: Intravitreal

Overview

ACM-007 is a preclinical-stage therapeutic candidate developed by ACM Biolabs for the treatment of retinal disorders. The program utilizes the company's proprietary Artificial Cell Membrane (ACM) technology, which employs polymer-based vesicles known as polymersomes to encapsulate and deliver therapeutic payloads. This delivery platform is designed to enhance the stability and sustained release of biologics or other therapeutic agents within the ocular environment, potentially improving treatment outcomes and reducing the frequency of intravitreal injections required for chronic retinal diseases.

Beyond the preview

Go deeper on ACM-007.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ACM-007.

Explore the full profile